MYOTONIC DYSTROPHY 1
Clinical trials for MYOTONIC DYSTROPHY 1 explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY 1 trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in early trial for rare muscle disease
Disease control CompletedThis study tested a new medicine called AOC 1001 in 38 adults with myotonic dystrophy type 1 (DM1), a genetic disease that causes muscle weakness and stiffness. The goal was to see if the drug is safe and how it works in the body. Participants received either the drug or a placeb…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug tested for muscle disease: first human trial shows promise
Disease control CompletedThis early-stage study tested a single dose of a new drug called PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo by …
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis study tested a drug called tideglusib in 16 adolescents and adults with a rare muscle disease called myotonic dystrophy type 1. The goal was to see if the drug is safe and if it helps with symptoms. Participants took either 400 mg or 1000 mg of tideglusib daily, and research…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated May 18, 2026 11:58 UTC
-
Experimental DM1 drug shows promise in long-term safety trial
Disease control CompletedThis study looked at the long-term safety of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 people who completed an earlier study received multiple doses of the drug by IV. Researchers tracked side effects and measured drug lev…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Hidden danger: muscle disease linked to deadly blood clots
Knowledge-focused CompletedThis study looked at 130 people to understand why those with myotonic dystrophy type 1 (DM1) have a 10-times higher risk of dangerous blood clots in the legs or lungs. Researchers tested blood clotting and gene activity to find the cause. The goal is to help prevent these life-th…
Matched conditions: MYOTONIC DYSTROPHY 1
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 26, 2026 12:03 UTC